This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Weinstein, I. B. Articles by Felsher, D. PubMed PubMed Citation Articles by Weinstein, I. B. Articles by Felsher, D. Related Collections Cellular Pathobiology Cellular Pathobiology: Cancer Genes and Genomics Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Point-Counterpoint

Oncogene Addiction

¹ Herbert Irving Comprehensive Cancer Center and ² Department of Medicine, Columbia University Medical Center, New York, New York

Requests for reprints: I. Bernard Weinstein, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, HHSC-1509, 701 West 168th Street, New York, NY 10032-2704. Phone: 212-305-6921; Fax: 212-305-6889; E-mail: ibw1{at}columbia.edu.

Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called "oncogene addiction," provides a rationale for molecular targeted therapy. The efficacy of this strategy requires novel methods, including integrative genomics and systems biology, to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers. Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction. [Cancer Res 2008;68(9):3077–80]

Reviews

Oncogene Addiction

¹ Herbert Irving Comprehensive Cancer Center and ² Department of Medicine, Columbia University Medical Center, New York, New York

Requests for reprints: I. Bernard Weinstein, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, HHSC-1509, 701 West 168th Street, New York, NY 10032-2704. Phone: 212-305-6921; Fax: 212-305-6889; E-mail: ibw1{at}columbia.edu.

Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called "oncogene addiction," provides a rationale for molecular targeted therapy. The efficacy of this strategy requires novel methods, including integrative genomics and systems biology, to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers. Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction. [Cancer Res 2008;68(9):3077–80]

Department of Medicine and Oncology, Stanford University, Stanford, California

This article has been cited by other articles:

				G. C. Prendergast From Sturm und Drang to Zebrafish Cancer Reviews Online Content, June 1, 2008; 2008(6): 11 - 11. [Full Text] [PDF]